A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Phase 1

Completed

• Conditions: Healthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa
• Interventions: Drug: KT-474/Placebo; Drug: KT-474

• Registration Number: NCT04772885
• Lead Sponsor: Kymera Therapeutics, Inc.

Brief Summary

KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.

Detailed Description

This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to five single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for 28 days of dosing. Separately, additional multiple dose cohorts evaluating once every other day and/or twice weekly dosing schedules at or below previously evaluated dose levels in healthy volunteers may be initiated.

Study Timeline

• Study First Submitted: 2021-02-12
• Study Start: 2021-02-23
• Study First Submitted QC: 2021-02-24
• Study First Posted: 2021-02-26
• Status Verified: 2022-10
• Primary Completion: 2022-10-20
• Study Completion: 2022-10-20
• Last Update Submitted: 2022-10-21
• Last Update Posted: 2022-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 154

Inclusion Criteria

1. Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2.
2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2.
3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
4. Agreement and ability to comply with all contraception requirements if applicable.
5. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Healthy Volunteer (Parts A and B)

Read More

Exclusion Criteria

1. Evidence or history of a clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
2. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
3. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
4. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding.
5. Healthy volunteers who have participated in any investigational drug or device clinical study within 3 months prior to first dosing on this study.
6. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening.

AD or HS Patient (Part C) Inclusion Criteria:

1. Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb).
2. Diagnosis of AD or HS for at least 6 months.
3. Patients with AD: having at least 10% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas).
4. Willingness and ability to comply with all contraception requirements as applicable based on reproductive status.
5. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling.
6. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and on admission.
7. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
8. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
9. Patients with HS: A total Abscess and Inflammatory Nodule count of ≥4 at baseline

AD or HS Patient (Parts C) Exclusion Criteria:

1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD or HS), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion (eg, conditions or findings that may expose a patient to unacceptable risk by study participation, confound the evaluation of treatment response or adverse events, or otherwise interfere with a patient's ability to complete the study).
2. Has an active systemic or soft tissue infection, including known actively-infected AD or HS skin lesion.
3. Treatment with an investigational product within 30 days or 5 half-lives preceding the first dose of investigational product (whichever is longer).
4. Use of prescription or nonprescription drugs including topical corticosteroids, vitaminic and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
5. Blood donation (excluding plasma donations and platelet donations) of approximately ≥400 mL within 3 months or ≥200 mL within a month prior to dosing.
6. History of sensitivity to heparin or heparin-induced thrombocytopenia.
7. Unwilling or unable to comply with the protocol procedures and/or assessments.
8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
9. Patients with HS: Fistula and Tunnel count of >20 at baseline.
10. Patients with AD: Active herpes infection or history of eczema herpeticum.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Single ascending dose cohorts in healthy subjects	KT-474/Placebo	Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
Multiple ascending dose cohorts in healthy subjects	KT-474/Placebo	Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
Food Effect Cohort in healthy subjects	KT-474/Placebo	Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.
Multiple dose cohort in HS and AD patients	KT-474	A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.
Multiple dose cohorts in healthy subjects	KT-474/Placebo	Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.

Primary Outcome Measures

Name	Time	Method
Incidence and severity of treatment emergent Adverse Events	up to 28 days
Incidence and frequency of use of concomitant medication	up to 28 days

Secondary Outcome Measures

Name	Time	Method
Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only)	up to 28 days
Time to maximum observed plasma concentration (Tmax)	up to 28 days
Terminal elimination half-life (t1/2)	up to 28 days
Mean residence time (MRT)	up to 28 days
Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]	up to 28 days
Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)]	up to 28 days
Maximum observed plasma concentration (Cmax)	up to 28 days
Apparent clearance (CL/F)	up to 28 days
Apparent volume of distribution (Vz/F)	up to 28 days
Renal clearance (CLR)	up to 28 days

Trial Locations

Locations (14)

Medical Dermatology Specialists; 🇺🇸 Phoenix, Arizona, United States

Southwest Skin Specialists 32nd St; 🇺🇸 Phoenix, Arizona, United States

Research Centers of America; 🇺🇸 Hollywood, Florida, United States

Encore Medical Research, LLC. - Hollywood; 🇺🇸 Hollywood, Florida, United States

Encore Medical Research, LLC. - Boynton Beach; 🇺🇸 Boynton Beach, Florida, United States

TKL Research; 🇺🇸 Fair Lawn, New Jersey, United States

Southwest Skin Specialists Tatum; 🇺🇸 Phoenix, Arizona, United States

Beatrice Keller Clinic; 🇺🇸 Sun City West, Arizona, United States

U.S. Dermatology Partners Jollyville; 🇺🇸 Austin, Texas, United States

Dermatology and Skin Cancer Center of Leawood; 🇺🇸 Leawood, Kansas, United States

Encore Medical Research, LLC. - Weston; 🇺🇸 Weston, Florida, United States

Dermatology and Skin Cancer Center of Overland Park; 🇺🇸 Overland Park, Kansas, United States

Dermatology and Skin Cancer Center of Lee's Summit; 🇺🇸 Lee's Summit, Missouri, United States

U.S. Dermatology Partners Cedar Park; 🇺🇸 Cedar Park, Texas, United States